Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177-DOTA-di-HSG peptide IMP-288
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Lutetium Lu 177-DOTA-di-HSG peptide IMP-288 (177Lu-IMP-288) is an investigational radiolabeled peptide therapeutic developed by Immunomedics (now Gilead Sciences) for use in pretargeted radioimmunotherapy (PRIT). It consists of the bivalent histamine-succinyl-glycine (HSG) hapten-peptide IMP-288 conjugated to the beta-emitting radionuclide lutetium-177 via a DOTA chelator. In the PRIT system, 177Lu-IMP-288 is administered following the injection of TF2, a trivalent bispecific antibody that targets both carcinoembryonic antigen (CEA/CEACAM5) on tumor cells and the HSG hapten on the peptide. This pretargeting strategy allows TF2 to localize to CEA-expressing tumor cells and clear from the circulation before 177Lu-IMP-288 is introduced, enabling rapid capture of the radiolabeled peptide at the tumor site and minimizing off-target radiation exposure to healthy tissues. 177Lu-IMP-288 has been evaluated in Phase I clinical trials for the treatment of advanced colorectal cancer and CEA-expressing small cell and non-small cell lung cancers.
- Other names
- lutetium-177 IMP-288lutetium177 IMP-288lutetium 177 IMP-288177Lu-IMP-288177Lu-DOTA-di-HSG-peptide IMP-288lutetium Lu 177-DOTA-di-HSG peptide IMP-288
02
Targets
Anti-histamine-succinyl-glycine binding site on the bispecific monoclonal antibodyCEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on lutetium Lu 177-DOTA-di-HSG peptide IMP-288.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177-DOTA-di-HSG peptide IMP-288.